LANDMARK LUNG CANCER CLINICAL STUDY BEING PRESENTED AT CHEST ANNUAL MEETING: GPS TECHNOLOGY MAY HELP PHYSICIANS DETECT LUNG CANCER AT ITS EARLY STAGES
Lung cancer remains the #1 cancer-related killer amongst men and women, and can impact anyone regardless of age or smoking history. Sadly, the disease is often caught in later stages, when patient outcomes are usually far less favorable. Research has shown that early detection and treatment of cancer has the potential to significantly improve patient outcomes and potentially save millions of lives worldwide.
In a major step forward in the early detection of lung cancer, researchers at the CHEST Annual Meeting are presenting new data from a landmark global clinical trial on a minimally invasive technology to aid in the early detection and preparation for treatment of this deadly disease.
Clinical data will be presented on the interim results of the NAVIGATE (Clinical Evaluation of superDimension™ Navigation System™ for Electromagnetic Navigation Bronchoscopy) study— the largest ever prospective, global multicenter clinical study to date on electromagnetic navigation bronchoscopy (ENB) using the superDimension™ navigation system.
Lead investigators will share early findings at CHEST from the first 500 patients on how superDimension™ navigation system use during ENB procedures provides physicians guided navigation and extended reach, allowing them to access small tumors and safely take tissue samples from the peripheral lung for diagnoses.
The superDimension™ navigation system uses LungGPS™ technology, the first of its kind to enable ENB procedures. The GPS technology allows physicians to proactively chart out their approach to biopsy lesions that exist in the peripheral lungs.
The superDimension™ navigation system has the potential to positively impact the future of lung care by:
§ Allowing physicians to pass sampling tools through bronchoscopes and reach the peripheral lung lesions that traditional approaches may not be able to reach
§ Enhancing ENB procedures to allow peripheral lung lesion biopsy, lesion localization with fiducial placement or dye marking to prepare for treatment, and endobronchial ultrasound-guided lymph node staging in the same minimally invasive anesthetic event
§ Improving patient safety by helping to reduce incidences of collapsed lung (pneumothorax)
Dr. Erik Folch, MD MSc, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital
Dr. Sandeep Khandar, MD, CVTSA Thoracic Surgical Director of Thoracic Oncology, Inova Fairfax Hospital
Tuesday October 25th 2016 at 8:45 AM PT, in room 411 of the Los Angeles Convention Center
§ Drs. Folch and Khandar’s presentation, Electromagnetic Navigation Bronchoscopy for Lung Lesion Evaluation in 500 Subjects: First Interim Analysis of the Prospective, Multicenter NAVIGATE Study
You may also visit the Medtronic booth (# 2100) to learn more and speak with lead investigators of the NAVIGATE study.
To schedule an interview with Dr. Folch or a member of the Medtronic team before, during or after CHEST, contact Glenn Silver, Lazar Partners at 646-871-8485 or [email protected].
Chief Media Strategist
L A Z A R P A R T N E R S L T D
420 Lexington Avenue, Suite 442
New York, NY 10170
Lazar Partners is a healthcare communications consultancy offering deep expertise in investor relations, public relations, marcomm, patient-to-patient communications, medical writing, DC relationship building and key opinion leader engagement. Led by a team of senior advisors with agency, life science corporate, journalism and financial experience we deliver personalized, results-oriented solutions for every client - from early stage to industry leaders.
The information contained in this transmission is privileged and confidential, and is solely intended for the above named individual or entity. If you are not the intended recipient or an employee responsible for delivering this document, you should be aware that any distribution, copying or communication of the information contained in this transmission is strictly prohibited. If you receive this transmission in error, please notify us immediately at the phone number listed above. Finally, the recipient should check this email and any attachments for the presence of viruses. The company accepts no liability for any damage caused by any virus transmitted by this email.